<DOC>
	<DOCNO>NCT02781272</DOCNO>
	<brief_summary>ANGLE develop Parsortix™ Cell Separation System ( Parsortix ) , automated system capable harvest rare circulate cell analysis sample peripheral blood base cellular size deformability . In small pilot study , scientist Medical University Vienna demonstrate measurement combination mRNA marker extract CTCs capture use Parsortix system could use identify woman ovarian cancer . This study design provide specimen optimization assay use clinical biomarker information ( i.e . demographic , image result and/or serum tumor marker ) combination mRNA extract rare cell blood woman present pelvic mass detection malignancy . Primary Objective : Optimization assay/algorithm differentiation woman benign pelvic mass malignant pelvic mass use clinical biomarker information ( i.e . demographic , image result and/or serum tumor marker ) combination mRNA marker extract rare cell isolated whole blood . Multiple serum protein marker mRNA marker measure , result compare actual clinical diagnosis make subject recognize method ( i.e . histopathology ) . Statistical modeling use combine clinical information , serum protein marker and/or mRNA marker estimation risk malignancy . If successful , result risk algorithm evaluate future , appropriately power , prospective study . Exploratory Objective : Use statistical modeling determine need and/or preliminary design mathematical algorithm combine clinical information , serum protein marker and/or mRNA marker estimation risk malignancy .</brief_summary>
	<brief_title>Evaluation Multiple Protein Molecular Biomarkers Estimate Risk Cancer Gynecology Patients Presenting With Pelvic Mass .</brief_title>
	<detailed_description>This study exploratory nature design hypothesis generate support design future study . Women diagnose pelvic mass ( ovarian , uterine , retroperitoneal , etc . ) schedule image guide biopsy , surgical biopsy surgical excision evaluation pelvic mass . It estimate approximately 200 woman enrol evaluation primary exploratory endpoint . Enrollment study continue beyond 200 woman necessary obtain minimum 50 evaluable woman histopathologically confirm malignancy , include ovarian , fallopian , peritoneal , endometrial , cervical , etc . Within 60 day prior pelvic mass evaluation procedure , subject must pelvic image study ( e.g . ultrasound , CT scan , MRI , etc . ) conduct read visualize pelvic mass accord current standard care . Results pelvic imaging study ( y ) record . Within 30 day prior , day pelvic mass evaluation procedure , collect 35mL whole blood one 5mL SST tube , must draw first , follow three separate 10mL EDTA tube . Serum SST tube use protein biomarker test . Blood EDTA tube pool process Parsortix™ System capture harvest rare cell . The captured rare cell elute ( harvest ) lysed , total RNA extract cell lysate evaluation multiple gene target . Imaging guide biopsy , surgical biopsy surgical excision evaluation pelvic mass perform qualified individual . Tissue sample send local pathology department histological examination accordance standard institutional practice . Results histopathological evaluation record , include final diagnosis along histological sub-type , available , stage , cancer disease identify . Where possible , representative fresh frozen tissue sample pelvic mass obtain research purpose evaluation mRNA gene target use cell harvest . Subjects consider negative malignancy : - subject undergoes surgery mass identify , ; - histopathological finding negative malignancy ( i.e . benign condition ) . Subjects consider positive malignancy : - histological examination tissue take time biopsy surgery confirm presence malignancy ( i.e . ovarian , primary peritoneal , fallopian tube , endometrial , uterine , cervical , metastatic cancer , etc. ) . For purpose enrollment , subject diagnose low malignant potential ( LMP ) / borderline tumor consider benign ( negative malignancy ) . However , two separate analysis final study data conduct : one subject diagnose low malignant potential ( LMP ) / borderline tumor classify negative malignancy second time subject classify positive malignancy . For subject diagnosed malignancy , bi-annual medical record review perform 5 year enrollment study collect information regard treatment response , chemotherapy sensitivity resistance , time recurrence , time progression overall survival . An algorithm prediction benign vs. malignant disease construct use clinical information , serum biomarkers mRNA marker . Additional analysis may perform within various histopathological diagnosis sub-groups . The variable selection algorithm construction do use various statistical method , logistic regression , hierarchal clustering , classification regression tree ( CART ) , ROC curve evaluation , sensitivity/specificity analysis , visual plotting determination threshold , etc . The inputs evaluation may include continuous variable ( e.g . age , ovary dominant mass dimension , serum biomarker result , mRNA expression level , etc . ) , categorical variable ( e.g . age group , biomarker result range , mRNA expression level range , etc . ) , and/or binary variable ( e.g . presence absence particular risk factor and/or image feature , age particular threshold , menopausal status , biomarker result particular threshold , mRNA expression level particular threshold , etc. ) . A threshold resulting algorithm ( ) output differentiate benign malignant disease ( subgroup thereof , epithelial ovarian cancer patient ) select optimize sensitivity set specificity ( e.g . maximize sensitivity minimum specificity level &gt; 80 % ) . Upon completion long-term follow-up period , association clinical data marker subject 's treatment response , chemotherapy sensitivity resistance , time recurrence , time progression overall survival assess use appropriate statistical method ( e.g . 2x2 table , correlation analysis , Cox hazard regression , Kaplan-Meier plotting , etc . ) .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>Women &gt; 18 year age ; Documented evidence pelvic mass imaging ; Selected undergo biopsy , laparotomy laparoscopy pathologic evaluation pelvic mass ; Willing able provide write informed consent . Known pregnancy ; Previous malignancy within past 5 year , exclude skin cancer ( squamous cell basal cell ) ; Unwilling unable follow protocol requirement provide informed consent .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>pelvic mass</keyword>
	<keyword>ovarian cancer</keyword>
	<keyword>gynecological cancer</keyword>
	<keyword>risk prediction</keyword>
</DOC>